GlassScriptPhysician profile
Joseph A Clever
NPI 1245438886
$3,523.46
in general payments reported to CMS, 2019-2025
20 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $469 · 2021: $460 · 2022: $155 · 2023: $187 · 2024: $912 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,303.61 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Tarsus Pharmaceuticals, INC. | $387.13 | 2024-2025 | Xdemvy |
| Allergan, INC. | $291.93 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $225.23 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $215.80 | 2023-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Aerie Pharmaceuticals, INC. | $172.71 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $155.10 | 2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $144.45 | 2021-2022 | |
| Ocular Therapeutix, INC. | $130.63 | 2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $114.03 | 2019-2025 | Cequa |
| Abbvie INC. | $92.91 | 2022-2025 | |
| Thea Pharma INC. | $55.45 | 2023-2024 | Iyuzeh |
| Harrow Eye, LLC | $50.29 | 2024 | Iheezo |
| Kala Pharmaceuticals, INC. | $47.64 | 2022 | |
| Omeros Corporation | $32.70 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.07 | 2025 | Tepezza |
| Biotissue Holdings INC. | $22.88 | 2025 | |
| Shire North American Group INC | $20.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.15 | 2023 | |
| Eyepoint US, INC. | $17.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Clever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.